QQQ   303.59 (-0.85%)
AAPL   151.73 (-1.79%)
MSFT   256.77 (-0.61%)
META   186.06 (-0.25%)
GOOGL   102.90 (-1.79%)
AMZN   102.18 (-1.17%)
TSLA   194.76 (+2.52%)
NVDA   210.89 (-0.05%)
NIO   10.93 (-2.32%)
BABA   105.45 (-0.83%)
AMD   83.68 (-2.80%)
T   19.58 (-1.26%)
F   13.14 (-0.68%)
MU   59.98 (-3.89%)
CGC   2.95 (+1.03%)
GE   82.35 (+0.48%)
DIS   109.87 (-0.76%)
AMC   6.80 (+11.84%)
PFE   43.76 (-0.68%)
PYPL   82.33 (-3.73%)
NFLX   361.48 (-1.21%)
QQQ   303.59 (-0.85%)
AAPL   151.73 (-1.79%)
MSFT   256.77 (-0.61%)
META   186.06 (-0.25%)
GOOGL   102.90 (-1.79%)
AMZN   102.18 (-1.17%)
TSLA   194.76 (+2.52%)
NVDA   210.89 (-0.05%)
NIO   10.93 (-2.32%)
BABA   105.45 (-0.83%)
AMD   83.68 (-2.80%)
T   19.58 (-1.26%)
F   13.14 (-0.68%)
MU   59.98 (-3.89%)
CGC   2.95 (+1.03%)
GE   82.35 (+0.48%)
DIS   109.87 (-0.76%)
AMC   6.80 (+11.84%)
PFE   43.76 (-0.68%)
PYPL   82.33 (-3.73%)
NFLX   361.48 (-1.21%)
QQQ   303.59 (-0.85%)
AAPL   151.73 (-1.79%)
MSFT   256.77 (-0.61%)
META   186.06 (-0.25%)
GOOGL   102.90 (-1.79%)
AMZN   102.18 (-1.17%)
TSLA   194.76 (+2.52%)
NVDA   210.89 (-0.05%)
NIO   10.93 (-2.32%)
BABA   105.45 (-0.83%)
AMD   83.68 (-2.80%)
T   19.58 (-1.26%)
F   13.14 (-0.68%)
MU   59.98 (-3.89%)
CGC   2.95 (+1.03%)
GE   82.35 (+0.48%)
DIS   109.87 (-0.76%)
AMC   6.80 (+11.84%)
PFE   43.76 (-0.68%)
PYPL   82.33 (-3.73%)
NFLX   361.48 (-1.21%)
QQQ   303.59 (-0.85%)
AAPL   151.73 (-1.79%)
MSFT   256.77 (-0.61%)
META   186.06 (-0.25%)
GOOGL   102.90 (-1.79%)
AMZN   102.18 (-1.17%)
TSLA   194.76 (+2.52%)
NVDA   210.89 (-0.05%)
NIO   10.93 (-2.32%)
BABA   105.45 (-0.83%)
AMD   83.68 (-2.80%)
T   19.58 (-1.26%)
F   13.14 (-0.68%)
MU   59.98 (-3.89%)
CGC   2.95 (+1.03%)
GE   82.35 (+0.48%)
DIS   109.87 (-0.76%)
AMC   6.80 (+11.84%)
PFE   43.76 (-0.68%)
PYPL   82.33 (-3.73%)
NFLX   361.48 (-1.21%)
NYSE:DNA

Ginkgo Bioworks - DNA Stock Forecast, Price & News

$1.96
-0.10 (-4.85%)
(As of 02/6/2023 12:00 AM ET)
Add
Compare
Today's Range
$1.93
$2.07
50-Day Range
$1.52
$2.19
52-Week Range
$1.45
$6.31
Volume
16.69 million shs
Average Volume
20.31 million shs
Market Capitalization
$3.80 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.92

Ginkgo Bioworks MarketRank™ Forecast

Analyst Rating
Hold
2.43 Rating Score
Upside/​Downside
202.0% Upside
$5.92 Price Target
Short Interest
Bearish
12.43% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.33mentions of Ginkgo Bioworks in the last 14 days
Based on 16 Articles This Week
Insider Trading
Selling Shares
$14.78 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.41) to ($0.34) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.97 out of 5 stars

Medical Sector

584th out of 1,027 stocks

Biological Products, Except Diagnostic Industry

92nd out of 169 stocks

DNA stock logo

About Ginkgo Bioworks (NYSE:DNA) Stock

Ginkgo Bioworks Holdings Inc. is a biotech company attempting to revolutionize the biotechnology industry by engineering completely new organisms. Founded in 2008 by Jason Kelly, Austin Che, Thomas Knight Jr. and Bartholomew Canton, the company operates a market-agnostic platform utilizing the latest technologies to pioneer the development of more sustainable biotechnology and bioengineering applications. 

Ginkgo Bioworks Holdings Inc. develops multiple platforms for food production, agriculture, industrial and pharmaceuticals. These platforms enable bioengineering applications across diverse markets, and the company customizes organisms for customers ranging from large companies to smaller startups. The company also creates proprietary software, algorithms and automation to engineer "customizable organisms" for their customers and the development of new products for the industrial and consumer markets. 

The company has earned multiple awards for its innovative technology in biologics, including the National Science Foundation's Innovation Corps Award, the National Academy of Engineering's Grand Challenges Award and the World Economic Forum's Technology Pioneers Award. 

Ginkgo Bioworks Holdings Inc. has partnered with prestigious organizations, including the Broad Institute of MIT, Harvard, Genomics England, the National Institutes of Health and the National Science Foundation's Innovation Corps to further their mission of making biotechnology more accessible to smaller and medium-sized organizations. 

Ginkgo Bioworks Holdings Inc. strives to revolutionize the biotech industry, attempting to pioneer the development of an ecosystem that will provide more sustainable and accessible biotechnology systems. With the help of innovative technology and strategic partnerships with prestigious organizations, Ginkgo Bioworks Holdings Inc. is well on its way to achieving this goal and making biotechnology more accessible to smaller and medium-sized organizations.

Ginkgo Bioworks Holdings Inc. has a market cap of approximately $2.97 billion, down from $3.98 in 2022. However, the company has seen rapid growth since 2020, increasing revenues from $3.8 million in 2017 to $313.8 million in 2022. 

Receive DNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ginkgo Bioworks and its competitors with MarketBeat's FREE daily newsletter.

DNA Stock News Headlines

"We need batteries. Literally everywhere."
Pretty much every technological megatrend today requires batteries. That includes EVs... 5G... AI... charging stations... and smart energy storage systems. Find out why the U.S. just added graphite to a list of super-critical minerals, calling it "essential for America's National Defense."
Ginkgo Bioworks (NYSE:DNA) Trading Up 4.1%
"We need batteries. Literally everywhere."
Pretty much every technological megatrend today requires batteries. That includes EVs... 5G... AI... charging stations... and smart energy storage systems. Find out why the U.S. just added graphite to a list of super-critical minerals, calling it "essential for America's National Defense."
Ginkgo Bioworks (NYSE: DNA)
Ginkgo Bioworks meets 2022 revenue outlook
Ginkgo Bioworks and the Ministry of Health of
See More Headlines
Receive DNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ginkgo Bioworks and its competitors with MarketBeat's FREE daily newsletter.

DNA Company Calendar

Last Earnings
11/14/2022
Today
2/06/2023
Next Earnings (Estimated)
3/27/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Fax
N/A
Employees
641
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.92
High Stock Price Forecast
$12.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+202.0%
Consensus Rating
Hold
Rating Score (0-4)
2.43
Research Coverage
7 Analysts

Profitability

Net Income
$-1,830,050,000.00
Net Margins
-668.49%
Pretax Margin
-670.21%

Debt

Sales & Book Value

Annual Sales
$313.84 million
Book Value
$0.93 per share

Miscellaneous

Outstanding Shares
1,939,980,000
Free Float
1,601,065,000
Market Cap
$3.80 billion
Optionable
Optionable
Beta
0.85

Key Executives

  • Dr. Jason Kelly (Age 41)
    Founder, CEO & Director
    Comp: $262.5k
  • Dr. Reshma P. Shetty (Age 41)
    Founder, Pres, COO & Director
    Comp: $262.5k
  • Mr. Mark E. Dmytruk (Age 51)
    Chief Financial Officer
    Comp: $439.5k
  • Mr. Thomas Knight Jr.
    Founder
  • Mr. Austin Che
    Founder, Head of Strategy & Treasurer
  • Mr. Bartholomew Canton
    Founder, CTO & Sec.
  • Marie E Fallon
    Chief Accounting Officer
  • Karen Tepichin
    Gen. Counsel & Sec.
  • Ms. Anna Marie Wagner
    Sr. VP of Corp. Devel.
  • Ms. Samantha Sutton
    Head of People













DNA Stock - Frequently Asked Questions

Should I buy or sell Ginkgo Bioworks stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ginkgo Bioworks in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" DNA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DNA, but not buy additional shares or sell existing shares.
View DNA analyst ratings
or view top-rated stocks.

What is Ginkgo Bioworks' stock price forecast for 2023?

7 analysts have issued 1-year price objectives for Ginkgo Bioworks' stock. Their DNA share price forecasts range from $3.00 to $12.00. On average, they expect the company's share price to reach $5.92 in the next year. This suggests a possible upside of 202.0% from the stock's current price.
View analysts price targets for DNA
or view top-rated stocks among Wall Street analysts.

How have DNA shares performed in 2023?

Ginkgo Bioworks' stock was trading at $1.69 at the start of the year. Since then, DNA stock has increased by 16.0% and is now trading at $1.96.
View the best growth stocks for 2023 here
.

Are investors shorting Ginkgo Bioworks?

Ginkgo Bioworks saw a increase in short interest during the month of December. As of December 30th, there was short interest totaling 126,250,000 shares, an increase of 10.5% from the December 15th total of 114,290,000 shares. Based on an average daily volume of 24,280,000 shares, the short-interest ratio is presently 5.2 days. Currently, 12.5% of the company's shares are short sold.
View Ginkgo Bioworks' Short Interest
.

When is Ginkgo Bioworks' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 27th 2023.
View our DNA earnings forecast
.

How were Ginkgo Bioworks' earnings last quarter?

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) issued its quarterly earnings data on Monday, November, 14th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by $0.15. The firm had revenue of $66.40 million for the quarter, compared to analysts' expectations of $54.28 million. Ginkgo Bioworks had a negative net margin of 668.49% and a negative trailing twelve-month return on equity of 85.90%.

What guidance has Ginkgo Bioworks issued on next quarter's earnings?

Ginkgo Bioworks updated its FY 2022 earnings guidance on Thursday, February, 2nd. The company provided EPS guidance of for the period. The company issued revenue guidance of $460.00 million-$480.00 million, compared to the consensus revenue estimate of $470.79 million.

What is Ginkgo Bioworks' stock symbol?

Ginkgo Bioworks trades on the New York Stock Exchange (NYSE) under the ticker symbol "DNA."

Who are Ginkgo Bioworks' major shareholders?

Ginkgo Bioworks' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (12.59%), ARK Investment Management LLC (7.44%), Sumitomo Mitsui Trust Holdings Inc. (1.93%), Equitec Proprietary Markets LLC (0.21%), Bourgeon Capital Management LLC (0.02%) and Polianta Ltd (0.02%). Insiders that own company stock include Barry Canton, Christian O Henry, Jason R Kelly, Marie E Fallon, Marijn E Dekkers, Mark E Dmytruk and Reshma P Shetty.
View institutional ownership trends
.

How do I buy shares of Ginkgo Bioworks?

Shares of DNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ginkgo Bioworks' stock price today?

One share of DNA stock can currently be purchased for approximately $1.96.

How much money does Ginkgo Bioworks make?

Ginkgo Bioworks (NYSE:DNA) has a market capitalization of $3.80 billion and generates $313.84 million in revenue each year. The company earns $-1,830,050,000.00 in net income (profit) each year or ($2.29) on an earnings per share basis.

How many employees does Ginkgo Bioworks have?

The company employs 641 workers across the globe.

How can I contact Ginkgo Bioworks?

Ginkgo Bioworks' mailing address is 955 Fifth Avenue, New York NY, 10075. The official website for the company is www.eagleequityptnrs.com. The company can be reached via phone at 877-442-5362 or via email at investors@ginkgobioworks.com.

This page (NYSE:DNA) was last updated on 2/6/2023 by MarketBeat.com Staff